HL-1186
Phase 2Small molecule
HL-1186 is one of 180 small molecule programs targeting Neuropathic Pain. It is currently in Phase 2.
6
Indications
7
Total Trials
7
Active Trials
179
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
131 competitors in Safety and Efficacy
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Actemra
RochePhase 3
Rayos
RRoxane Laboratories
Phase 3
Humira
RRanbaxy Laboratories Limited
Phase 3
Empaveli
Apellis PharmaceuticalsPhase 3
CAB LA
GSKPhase 3
B/F/TAF
GileadPhase 3
Nuzyra
PParatek Pharmaceuticals Inc
Phase 3
Trodelvy
GileadPhase 2
Bomedemstat
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Post Operative Pain2 trials
Tics1 trial
Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants
Recruiting·SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.·Phase 1·NCT06912295·76 enrolled
Safety and Efficacy1 trial
Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery
Recruiting·SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT07147049·72 enrolled
Neuropathic Pain1 trial
Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain
Not yet recruiting·SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT07159243·180 enrolled
Postoperative Pain Management1 trial
Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery
Recruiting·SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT07311369·40 enrolled
1 more indication
Post Herpetic Neuralgia (PHN)1 trial
A Clinical Trial to Evaluate the Efficacy and Safety of HL-1186 Tablet in the Treatment of Postherpetic Neuralgia
Recruiting·SShanghai Yidian Pharmaceutical Technology Development Co., Ltd.·Phase 2·NCT07758920·200 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HL-1186. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details